卵巢癌新辅助化疗的临床研究进展

黄妙瑜，陈递林

（1 .暨南大学第二临床医学院，广东 深圳，518020 ；2 .深圳市人民医院妇科，广东 深圳，518020）

浏览次数：128次 下载次数：417次

摘要：

卵巢癌是继宫颈癌、子宫内膜癌之后的第三大女性生殖系统恶性肿瘤，也是威胁女性身心健康的隐形杀手。卵巢癌恶性程度高，病情发展迅速，容易复发，晚期卵巢癌预后较差，且治疗方法相对较少。新辅助化疗（NACT）是针对恶性肿瘤而研发的一类新型化疗技术。对于常规治疗无效、肿瘤进展快、复发及远处转移、无法手术切除肿瘤的患者，新辅助化疗提供了一种先化疗再手术的方案，为卵巢癌临床治疗提供了新的途径。为此，该篇文章对卵巢癌新辅助化疗的临床研究进展进行论述。

关键词：卵巢癌；新辅助化疗；初始肿瘤细胞减灭术

中图分类号：R737.31文献标志码：A文章编号：2096-1413(2017)11-0197-02

The clinical research progress of neoadjuvant chemotherapy for ovarian cancer
HUANG Miao-yu1,2, CHEN Di-lin1,2
(1. the 2nd Clinica Medical College of Jinan University, Shenzhen 518020; 2. Department of Gynecology, the people's Hospital of Shenzhen, Shenzhen 518020, China)

ABSTRACT: Ovarian cancer is the third of the most common malignant tumor of female reproductive system after cervical cancer and endometrial cancer, it is also a potential killer which threatens women' health. Ovarian cancer is a high malignancy with invasive fast -growing and high recurrence rate, with poor prognosis and lack of relative treatment. Neoadjuvant chemotherapy (NACT) is a new type of chemotherapy for malignant tumor. For the patients who can't be treated with conventional therapies, with the rapid tumor progression, recurrence and distant metastasis and unresectable tumors, NACT services a new treatment method of receiving chemotherapy and followed by surgery, which carries out a new way for the clinical treatment of ovarian cancer. To this end, this article discusses the clinical research progress of neoadjuvant chemotherapy for ovarian cancer.
KEYWORDS: ovarian cancer; neoadjuvant chemotherapy; primary debulking surgery

参考文献：
[1] 边策,姚奎,赵际童,等.晚期卵巢癌患者对新辅助化疗的反应及预后差异分析[J].实用妇产科杂志,2015,12(12):942-947.
[2] 臧翊辰,陈爱平,丁朝霞,等.卵巢癌新辅助化疗患者CA125水平对临床结局的预测分析[J].现代妇产科进展,2015,24(3):217-219.
[3] ZENG J,YIN J,SONG X,et al.Reduction of CA125 levels during neoadjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma[J].J Cancer,2016,7 (15):2327-2332.
[4] 徐正美.新辅助化疗联合中间性肿瘤细胞减灭术治疗晚期上皮性卵巢癌及卵巢癌预后影响因素的临床分析[D].广州:南方医科大学,2013.
[5] 边策,綦小蓉,姚奎,等.新辅助化疗对晚期卵巢癌治疗应用价值的评估及多因素分析[J].实用妇产科杂志,2016,32(4):266-271.
[6] 冯仙明,陈焕伟,王博,等.初始化疗或手术对芋期卵巢癌的临床疗效分析[J].肿瘤药学,2016,6(5):375-378.
[7] Society of Gynecologic Oncology.Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline[J]. Gynecol Oncol,2016,143(1):3-15.
[8] 徐正美.新辅助化疗联合中间性肿瘤细胞减灭术治疗晚期上皮性卵巢癌及卵巢癌预后影响因素的临床分析[D].广州:南方医科大学,2013.
[9] 何海新,林安,李玲,等.中间性细胞减灭术联合新辅助化疗治疗中晚期上皮性卵巢癌的临床研究[J].中国卫生标准管理,2016,7(10):15-17.
[10] KESSOUS R,LASKOV I,ABITBOL J,et al.Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer[J].Gynecol On col,2016,doi:10.1016/j.ygyno.2016.12.017.
[11] 孟兆珂.紫杉醇与环磷酰胺治疗卵巢癌的疗效及毒性作用评价[J].临床医药文献电子杂志,2015,2(27):5734-5735.
[12] 商莉.晚期卵巢癌新辅助化疗与手术治疗的临床研究[J].宁夏医学杂志,2011,33(7):618-619.
[13] DESSAI SB,CHAKRABORTY S,BABU TVS,et al.Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.[J].Indian J Cancer,2016,5(2):280-283.
[14] XU X,DENG F,LV M,et al.The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer[J].Arch Gynecol Obstet,2017,295(2):451-458.
[15] BURGER RA,BRADY MF,BOOKMAN MA,et al.Update of randomized trials in first-line treatment[J].Ann Oncol,2011,22(s8):52-60.
[16] 董文惠.紫杉醇联合卡铂化疗治疗卵巢癌的临床疗效[D].长春:吉 林大学,2013.